A β-Blocker Trial in Dialysis Patients: Is It Feasible and Worthwhile?
Authors:
- 1 June 2016
- journal article
- editorial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 67 (6) , 822-825
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Patterns in blood pressure medication use in US incident dialysis patients over the first 6 monthsBMC Nephrology, 2013
- The Increasing Prevalence of Atrial Fibrillation among Hemodialysis PatientsJournal of the American Society of Nephrology, 2011
- Prognostic Value of Reduced Left Ventricular Ejection Fraction at Start of Hemodialysis Therapy on Cardiovascular and All-Cause Mortality in End-Stage Renal Disease PatientsClinical Journal of the American Society of Nephrology, 2010
- Left Ventricular Mass in Chronic Kidney Disease and ESRDClinical Journal of the American Society of Nephrology, 2009
- Left ventricular dysfunction in the haemodialysis populationClinical Kidney Journal, 2008
- Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood FlowClinical Journal of the American Society of Nephrology, 2008
- Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progressionKidney International, 2004
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathyJACC, 2003
- β-Blockers in Chronic Heart FailureCirculation, 2003
- A Double-Blind Trial of Metoprolol in Acute Myocardial InfarctionNew England Journal of Medicine, 1983